This is a prospective, randomized, double-blinded, placebo-controlled, pilot study to assess the preliminary efficacy and safety of hydroxychloroquine for the treatment of patients with lower respiratory tract SARS-CoV-2 infection.
A total of 40 participants are planned for enrollment. Those enrolled into this study will be
randomized 1:1 to receive either hydroxychloroquine or placebo control.
Participants will receive their study intervention for 5 days, after which they will be
considered off protocol- directed therapy and receive medical management of their disease
according to institutional standards. Participants may be followed for up to 180 days from
initiating protocol therapy for clinical outcome, after which they will discontinue study
participation.
Drug: Hydroxychloroquine
Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
Drug: Placebo
A placebo is a pill that looks like the study drug but has no real medicine in it.
Inclusion Criteria:
1. Ability to understand and the willingness to sign a written informed consent document.
2. Individuals aged ≥ 18 years of all races and ethnic groups.
3. Must have documented positive test result for SARS-CoV-2 (COVID19), or high clinical
suspicion for SARS-CoV-2 based on presence of typical clinical findings (e.g., fever,
respiratory symptoms, pulmonary abnormalities on chest X-ray or CT scan), lack of
alternative diagnosis, and history of exposure to a known case of SARS-CoV- 2
infection within the past 14 days
4. Not receiving institutional therapy for treatment of SARS-CoV-2, including (but not
limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational
agent(s).
5. Must meet at least one of the following clinical stratifications:
1. Have at least 1 minor criterion per ATS criteria (refer to Appendix A), or
2. Have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g.,
X-ray or computed tomography [CT]), or
3. High risk for poor outcome, as defined by any one of the following:
i. Age ≥ 60 years old ii. Underlying medical comorbidities, defined as:
- Serious cardiovascular disease
- Poorly controlled diabetes (i.e., A1c levels >7%)
- Chronic kidney disease requiring dialysis
- Significant liver disease (Pugh-Child B or C)
- Severe obesity (body mass index [BMI] ≥ 40)
- Chronic respiratory disease (e.g., COPD)
- Hypertension, defined as blood pressure ≥ 140 / 90 mmHg iii. Solid organ or stem
cell transplant recipient iv. Diagnosis of solid or hematologic malignancy being
treated with systemic chemotherapy v. Receipt of biologic agent or prednisone >
0.5 mg/kg/day (or equivalent)
6. Patient must be within 5 days of symptom onset, as determined by clinical team.
7. Participants with preexisting auditory damage are allowed.
8. Participants with a history of epilepsy are allowed.
9. Female participants of childbearing potential (FOCBP) must have a negative serum or
urine pregnancy test (per institutional standards) prior to the start of study drug.
10. FOCBP must agree to use highly-effective method(s) of contraception (Appendix B)
during the study and for 1 months after the last dose of study drug. FOCBP are those
who have not been surgically sterilized or have not been free from menses for >1 year
without an alternative medical cause.
11. Male participants must agree to use an adequate method of contraception (Appendix B)
starting with the first dose of study therapy through at least 1 months after the last
dose of study drug.
12. Participant must agree to not breastfeed during the study or for 30 days after the
last dose of study treatment.
Exclusion Criteria:
1. The patient has serious and/or uncontrolled preexisting medical condition(s) that, in
the judgment of the investigator, would preclude participation in this study.
2. Judgment by the investigator that the patient should not participate in the study if
the patient is unlikely to comply with study procedures, restrictions and
requirements.
3. Psychiatric illness/social situations, or any condition that, in the opinion of the
investigator, would interfere with evaluation of study treatment or interpretation of
participant safety or study results, or substantially increase risk of incurring AEs,
or compromise the ability of the patient to give written informed consent.
4. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as
judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic
arrhythmia, congestive heart failure, QTcF prolongation >500 ms, electrolyte
disturbances, etc.), or participants with congenital long QT syndrome
5. Patients with Myesthenia Gravis or other neuromuscular disorders
6. Patients with history of psoriasis.
a. May be waived at the discretion of the PI
7. Patients with history of porphyria
a. May be waived at the discretion of the PI
8. Concomitant use of other antiviral agents for the study's duration, but may be waived
at discretion of the Principal Investigator
9. Hypersensitivity to the study agent, or any of its excipients.
10. Females who are pregnant or lactating.
Oregon Health and Science University
Portland, Oregon, United States
Marcel Curlin, MD, Principal Investigator
Oregon Health and Science University